Literature DB >> 14525790

Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.

Randy S Longman1, Andrew H Talal, Ira M Jacobson, Matthew L Albert, Charles M Rice.   

Abstract

The absence of expanded numbers of hepatitis C virus (HCV)-reactive CD8(+) T lymphocytes (CTLs) in patients chronically infected with HCV has led to the investigation of dendritic cell (DC) function in this population as a potential cause for this defect. Several studies have shown evidence for impaired monocyte-derived DCs in chronically infected patients. As it is difficult to reconcile these data with the fact that patients with chronic HCV are immune competent, we re-evaluated this finding, carefully assessing phenotypic markers and functional activity of patient DCs as compared with noninfected controls. In contrast to these prior studies, DCs from 13 of 13 chronic HCV patients expressed typical maturation markers. These mature DCs were capable of priming allogeneic T lymphocytes, as well as stimulating influenza-specific memory T cells. This finding is consistent with clinical and immunologic data that the deficit in the patient's immune repertoire is HCV-specific and suggests that refined models are required for understanding the role of DCs in HCV pathogenesis.

Entities:  

Mesh:

Year:  2003        PMID: 14525790     DOI: 10.1182/blood-2003-04-1339

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.

Authors:  Lars-A Ormandy; Anatol Farber; Tobias Cantz; Susanne Petrykowska; Heiner Wedemeyer; Monique Horning; Frank Lehner; Michael-P Manns; Firouzeh Korangy; Tim-F Greten
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 2.  Mechanisms of HCV survival in the host.

Authors:  Ella H Sklan; Prista Charuworn; Philip S Pang; Jeffrey S Glenn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

3.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 4.  Dendritic cells in viral pathogenesis: protective or defective?

Authors:  Gabriele Pollara; Antonia Kwan; Philippa J Newton; Matthew E Handley; Benjamin M Chain; David R Katz
Journal:  Int J Exp Pathol       Date:  2005-08       Impact factor: 1.925

Review 5.  Dendritic cells: The warriors upfront-turned defunct in chronic hepatitis C infection.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-09-08

6.  Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells.

Authors:  Hua Liang; Rodney S Russell; Nicole L Yonkers; David McDonald; Benigno Rodriguez; Clifford V Harding; Donald D Anthony
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

7.  Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation.

Authors:  Irene S Ludwig; Annemarie N Lekkerkerker; Erik Depla; Fons Bosman; René J P Musters; Stany Depraetere; Yvette van Kooyk; Teunis B H Geijtenbeek
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 8.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

10.  Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells.

Authors:  A Takaki; M Tatsukawa; Y Iwasaki; K Koike; Y Noguchi; H Shiraha; K Sakaguchi; E Nakayama; K Yamamoto
Journal:  J Viral Hepat       Date:  2009-10-04       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.